Pharmacogenomic approach reveals a role for the xc- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 949-958

  Pham, Anh Nhan ^a   Blower, Paul E ^b   Alvarado, Omar ^a   Ravula, Ranadheer ^a   Gout, Peter W ^c   Huang, Ying ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYPHENYLGLYCINE; ACETYLCYSTEINE; ANTIPORTER; BUTHIONINE SULFOXIMINE; CELASTROL; CYSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELDANAMYCIN; GLUTAMIC ACID; HEAT SHOCK PROTEIN 90; HYDROXYPRISTIMERIN; HYDROXYTINGENONE; NSC 270057; NSC 684506; NSC 70931; PROTEIN; QUINONE DERIVATIVE; SALAZOSULFAPYRIDINE; SLC7A11 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CHEMOSENSITIZATION; CORRELATION ANALYSIS; CULTURE MEDIUM; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; GLIOMA; HUMAN; HUMAN CELL; LIGHT CHAIN; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH;

AMINO ACID TRANSPORT SYSTEM Y+; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; RNA, SMALL INTERFERING; SULFASALAZINE; TRITERPENES;

EID: 77249097525     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162248     Document Type: Article

References (39)

1. Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, and Ronai ZA (2007) Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res 13:6769-6778.
2. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, and Rudman D (1984) Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 87:770-776.
3. Chou TC, Motzer RJ, Tong Y, and Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524.
4. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
5. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, and Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25:7101-7110.
6. Chung WJ and Sontheimer H (2009) Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem 110:182-193.
7. Corson TW and Crews CM (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130:769-774.
8. -. J Med Chem 50:1896-1906.
9. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, and Wang YZ (2007) Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67:162-171.
10. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, and Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.
11. - cystine transporter: a new action for an old drug. Leukemia 15:1633-1640.
12. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, and Buckley AR (1997) Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 11:1329-1337.
13. Gout PW, Simms CR, and Robertson MC (2003) In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 14:21-29.
14. Guastavino E, Litwin NH, Heffes Nahmod L, and Licastro R (1988) Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment. Acta Gastroenterol Latinoam 18:107-113.
15. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, and Bates GP (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13:1389-1405.
16. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, and Golub TR (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321-330.
17. Huang Y (2007) Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26:183-201.
18. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, and Sadée W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-4301.
19. Huang Y, Blower PE, Liu R, Dai Z, Pham AN, Moon H, Fang J, and Sadee W (2007) Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1. Pharm Res 24:1702-1712.
20. Huang Y, Dai Z, Barbacioru C, and Sadée W (2005) Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65:7446-7454.
21. Huang Y, Penchala S, Pham AN, and Wang J (2008a) Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin Drug Metab Toxicol 4:237-254.
22. Huang Y and Sadée W (2006) Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239:168-182.
23. Huang Y, Zhou Y, Fan Y, and Zhou D (2008b) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264:101-106.
24. Ishii T, Bannai S, and Sugita Y (1981) Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. J Biol Chem 256:12387-12392.
25. Kupfer R, Dwyer-Nield LD, Malkinson AM, and Thompson JA (2002) Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4- methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity. Chem Res Toxicol 15:1106-1112.
26. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, and Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935.
27. Liu R, Blower PE, Pham AN, Fang J, Dai Z, Wise C, Green B, Teitel CH, Ning B, Ling W, Lyn-Cook BD, Kadlubar FF, Sadée W, and Huang Y (2007) Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol 72:1637-1646.
28. - cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99:464-472.
29. - cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 215:593-602.
30. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61.
31. Sato H, Tamba M, Ishii T, and Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274:11455-11458.
32. Savaskan NE, Hahnen E, and Eyupoglu IY (2009) The x(c)(-) cystine/glutamate antiporter (xCT) as a potential target for therapy of cancer: yet another cytotoxic anticancer approach? J Cell Physiol 220:531-532.
33. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, and Eyüpoglu IY (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14:629-632.
34. Sethi G, Ahn KS, Pandey MK, and Aggarwal BB (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109:2727-2735.
35. Sontheimer H (2008) A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 105:287-295.
36. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, and Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447:532-542.
37. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, and Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349.
38. Wu G, Fang YZ, Yang S, Lupton JR, and Turner ND (2004) Glutathione metabolism and its implications for health. J Nutr 134:489-492.
39. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, and Sun D (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7:162-170.